Product Description
Mechanisms of Action: TEM1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Morphotek
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Melanoma|Colorectal Cancer|Sarcoma
Phase 1: Hepatocellular Carcinoma|Gastrointestinal Cancer|Oncology Solid Tumor Unspecified|Chronic Lymphoid Leukemia|Lymphoproliferative Disorders|Lymphomatoid Granulomatosis|Burkitt Lymphoma|Immunoblastic Lymphadenopathy|Intraocular Lymphoma|B-Cell Marginal Zone Lymphoma|T-Cell Peripheral Lymphoma|Adult T-Cell Leukemia-Lymphoma|Large Granular Lymphocytic Leukemia|Hairy Cell Leukemia|Mantle-Cell Lymphoma|T-Cell Cutaneous Lymphoma|Diffuse Large B-Cell Lymphoma|Large-Cell Immunoblastic Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Leukemia, Plasma Cell|Granular Cell Tumor|Extranodal NK-T-Cell Lymphoma|Large-Cell Anaplastic Lymphoma|Waldenstrom Macroglobulinemia|Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Mycosis Fungoides|Plasmablastic Lymphoma|Sezary Syndrome|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Testicular Cancer|Follicular Lymphoma|Soft Tissue Cancer|Nose Cancer|Lung Cancer|Endometrial Cancer|Neuroectodermal Tumors|Breast Cancer|Colorectal Cancer|Sarcoma|Ovarian Cancer|Pancreatic Cancer|Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2011-001282-40 | P2 |
Completed |
Melanoma |
2021-02-25 |
|
| MORAb-004-203 Soft Tissue Sarcoma Study | P2 |
Completed |
Sarcoma |
2016-08-02 |
|
| MORAb-004-J081-103) | P1 |
Completed |
Gastrointestinal Cancer|Hepatocellular Carcinoma |
2016-07-01 |
|
| SOURCE | P2 |
Completed |
Sarcoma |
2015-08-11 |